MEDPLUS
Medplus Health Services Limited
Each stock's 10,000-path forecast, rendered as light.
Medplus Health Services Limited (MEDPLUS) Stock Analysis & Case Study
Is MEDPLUS a good buy? The data-driven verdict.
Medplus Health Services Limited (MEDPLUS) trades at ₹700,on the numbers it tread carefully, a Downstox Snapshot Score of 33/100.
On the numbers, Medplus Health Services Limited (MEDPLUS) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 40.0× earnings, ROE of 11.6%, a 57% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
MEDPLUS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How MEDPLUS ranks against the 2,371 companies in our screener
- MEDPLUS's market cap of 8,413 Cr ranks in the 73rd percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- MEDPLUS's book value of ₹165 ranks in the 67th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- MEDPLUS's promoter holding of 40.2% ranks in the 16th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- MEDPLUS's 3-year profit (PAT) growth of 66.0% ranks in the 88th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- MEDPLUS's 3-year revenue growth of 15.0% ranks in the 63rd percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- MEDPLUS's debt-to-equity ratio of 0.72x is lower than 24% of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
Is MEDPLUS overvalued? MEDPLUS P/E vs peers
MEDPLUS trades at 40.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
MEDPLUS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 4.5y of MEDPLUS history (-10%/yr drift, 31%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| MEDPLUS 2027 | ₹499 | ₹742 | ₹1,104 | +6% |
| MEDPLUS 2028 | ₹445 | ₹787 | ₹1,393 | +12% |
| MEDPLUS 2029 | ₹419 | ₹835 | ₹1,663 | +19% |
| MEDPLUS 2030 | ₹396 | ₹885 | ₹1,979 | +26% |
| MEDPLUS 2031 | ₹377 | ₹938 | ₹2,335 | +34% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability MEDPLUS goes up, or doubles?
The bull case for MEDPLUS
- Medplus Health Services Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,663.
The bear case & risks
- MEDPLUS's P/E of 40.0x is lower than 34% of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- MEDPLUS's return on equity of 11.6% ranks in the 58th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹419.
MEDPLUS volatility & expected range, how bumpy is the ride?
Over the last 4.5 years MEDPLUS compounded at -10%/year with annualized volatility of 31%. That volatility implies a 1-year 80% range of ₹499-₹1,104, the honest backbone behind any single price target.
MEDPLUS price forecast, the full 60-month probability fan
MEDPLUS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds MEDPLUS hits common targets within the simulated horizon?
Full multi-horizon detail on the MEDPLUS price target & forecast page.
MEDPLUS Piotroski F-Score: 5/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. MEDPLUS scores 5/8, mixed financial health.
MEDPLUS MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy MEDPLUS with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 30.43% | 3.3× |
| Groww | 30.53% | 3.3× |
| Dhan | 49.00% | 2.0× |
| Kotak Neo | 34.97% | 2.9× |
| Paytm Money | 40.58% | 2.5× |
| PocketfulCHEAPEST | 29.05% | 3.4× |
| Fyers | 50.00% | 2.0× |
| Anand Rathi | 35.00% | 2.9× |
| Bajaj Broking | 49.00% | 2.0× |
| Share India | 30.51% | 3.3× |
Compare every broker on the MEDPLUS MTF page.
About Medplus Health Services Limited: sector, index & market-cap context
Medplus Health Services Limited (MEDPLUS) is a small-cap NSE-listed company, with a market capitalisation of ₹8,413 Cr. See more stocks on our screener.
How the MEDPLUS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Medplus Health Services Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
MEDPLUS analysis, FAQs
Is Medplus Health Services Limited (MEDPLUS) a good buy?
On the numbers, Medplus Health Services Limited (MEDPLUS) tread carefully, a Downstox Snapshot Score of 33/100, weighing expensive at 40.0× earnings, ROE of 11.6%, a 57% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is MEDPLUS overvalued or undervalued?
MEDPLUS trades at 40.0× earnings, expensive versus the ~22× long-run Nifty average.
What is the MEDPLUS share price target for 2031?
MEDPLUS's probability-weighted 2031 median target is ₹938, with an 80% range of ₹377-₹2,335 (10,000-path Monte-Carlo).
What is the probability MEDPLUS doubles in 5 years?
The modelled probability of MEDPLUS reaching ₹1,401 (2×) within 5 years is 29%.
What is the bull case for MEDPLUS?
Medplus Health Services Limited is part of the nifty500 universe with live, tracked fundamentals on Downstox.
What are the risks in MEDPLUS?
MEDPLUS's P/E of 40.0x is lower than 34% of the 2,371 NSE companies in our screener, as of 8 Aug 2026. MEDPLUS's return on equity of 11.6% ranks in the 58th percentile of the 2,371 NSE companies in our screener, as of 8 Aug 2026.